Lagevrio Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Lagevrio (molnupiravir) and your pharmacy told you it's unavailable, you're probably wondering whether this is a shortage — and if so, what you can do about it. This article gives you the clearest picture possible of Lagevrio availability in 2026.

Is Lagevrio on the FDA Shortage List in 2026?

As of 2026, Lagevrio is not listed on the FDA's official drug shortage list. Merck continues to manufacture and distribute molnupiravir through commercial channels. On a national level, supply exists. However — and this is crucial — 'not in a formal shortage' does not mean 'easy to find at your local pharmacy.'

The Real Story: A Distribution and Stocking Problem

The challenge with Lagevrio in 2026 is not manufacturing capacity — it's a mismatch between where supply sits and where patients need it. Several factors drive this:

Government distribution has ended. All HHS-distributed Lagevrio stock expired by February 27, 2025. Lagevrio is now sold exclusively through commercial pharmacy channels — meaning pharmacies must purchase it themselves and take on financial risk.

Pharmacies under-stock due to high cost. A full course of Lagevrio costs over $1,100 at retail. Pharmacies that stock it risk that cost if doses expire before being dispensed.

Lagevrio is a second-line treatment. Paxlovid is the preferred first-line antiviral for most COVID patients. Lagevrio is prescribed mainly when Paxlovid can't be used — a smaller patient population — giving pharmacies less incentive to stock it.

Seasonal surge demand is unpredictable. COVID cases spike in fall and winter. Even pharmacies that carry some Lagevrio can deplete their small stock within days during a surge, then go weeks without a new shipment.

A Brief History of Lagevrio Availability

Understanding how we got here helps contextualize what's happening now:

December 2021: FDA issues Emergency Use Authorization for molnupiravir (Lagevrio). U.S. government purchases approximately 3.1 million treatment courses.

2022–2023: Government distributes Lagevrio at no cost through Test to Treat sites and partnered pharmacies. Wide availability for eligible patients.

Late 2023: Government stops purchasing and distributing Lagevrio commercially. Medication transitions to standard commercial pharmacy channels.

February 2025: All remaining HHS-distributed Lagevrio expires. No more government-sourced free Lagevrio available.

2026: Lagevrio available commercially only. Stocking varies widely by pharmacy. Seasonal access issues continue.

What Patients Should Do Right Now

If you've been prescribed Lagevrio and your pharmacy is out, here's your action plan:

Use medfinder: Visit medfinder.com to have pharmacies near you contacted on your behalf. You'll get results texted to you.

Expand your search: Call independent pharmacies and hospital outpatient pharmacies — they're often better stocked for specialty antivirals.

Contact your prescriber immediately: They may know which pharmacies have stock, or can help you pivot to an alternative treatment before your 5-day window closes.

Consider alternatives: If Lagevrio is unavailable and you're running out of time, Paxlovid or Remdesivir may be options. See our guide to Lagevrio alternatives.

Will Lagevrio Availability Improve?

In the near term, significant improvement is unlikely without either a policy change that incentivizes pharmacies to stock more Lagevrio, or a major shift in prescribing patterns. Paxlovid is likely to remain the first-line treatment, and Lagevrio will likely continue to occupy a smaller, second-line role. For patients who specifically need it, the availability problem will persist unless you proactively search pharmacies before you actually need it.